论文部分内容阅读
目的观察保妇康栓联合重组人干扰素治疗慢性宫颈炎的临床效果。方法将2014年3月-2016年3月收治的慢性宫颈炎患者212例根据治疗方法不同分为观察组(n=107)和对照组(n=105)。对照组给予重组人干扰素治疗,观察组在对照组治疗的基础上联合保妇康栓治疗。比较2组临床疗效及症状积分。结果观察组总有效率为95.33%明显好于对照组的84.76%,差异有统计学意义(χ2=-3.883,P=0.00)。治疗前2组症状积分比较差异无统计学意义(P>0.05),治疗后2组分泌物及宫颈病变程度积分均显著下降(P<0.05),且观察组治疗后各症状积分低于对照组,差异均有统计学意义(P<0.05)。结论保妇康栓联合重组人干扰素治疗慢性宫颈炎疗效显著,可明显减轻患者症状,值得临床推广应用。
Objective To observe the clinical effect of Baofukang Suppository combined with recombinant human interferon in the treatment of chronic cervicitis. Methods 212 patients with chronic cervicitis admitted from March 2014 to March 2016 were divided into observation group (n = 107) and control group (n = 105) according to the different treatment methods. The control group was treated with recombinant human interferon. The observation group was treated with Baofukang suppository on the basis of the control group. The clinical efficacy and symptom scores of two groups were compared. Results The total effective rate was 95.33% in the observation group was significantly better than 84.76% in the control group, the difference was statistically significant (χ2 = -3.883, P = 0.00). There was no significant difference in symptom scores between the two groups before treatment (P> 0.05). The scores of secretions and cervix lesions decreased significantly after treatment (P <0.05), and the score of each symptom in the observation group was lower than that in the control group , The differences were statistically significant (P <0.05). Conclusion Baofukang Suppository combined with recombinant human interferon in the treatment of chronic cervicitis significant effect, can significantly reduce the symptoms of patients, it is worth clinical application.